This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

Biogen files reply, supports dismissing product-hopping claims in US case

( December 16, 2025, 23:31 GMT | Official Statement) -- MLex Summary: Biogen filed a reply in support of its motion to dismiss amended claims accusing it of using a “market switch” to unlawfully impair competition from generic versions of its brand-name drug Tecfidera. Biogen said that plaintiffs fail to allege actual coercion and still have not alleged foreclosure, including because they concede that health plans choose their pharmacy benefit managers and formularies and because their theory largely challenges equal treatment of the at-issue drugs.See attached file. ...

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login

Documents

Related Sections